3ET0

Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid

3ET0 の概要

• エントリーDOI: 10.2210/pdb3et0/pdb
• 関連するPDBエントリー: 3ET1 3ET2 3ET3
• 分子名称: Peroxisome proliferator-activated receptor gamma, 3-(5-methoxy-1H-indol-3-yl)propanoic acid, alpha-D-glucopyranose, ... (4 entities in total)
• 機能のキーワード: ppar, pparg, ppargamma, drug discovery, diabetes, adiponectin, metabolic disease, fragment-based drug discovery, scaffold-based drug discovery, activator, alternative splicing, diabetes mellitus, disease mutation, dna-binding, metal-binding, nucleus, obesity, phosphoprotein, polymorphism, receptor, transcription, transcription regulation, zinc, zinc-finger
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 67150.77

構造登録者

Zhang, K.Y.J.,Wang, W. (登録日: 2008-10-06, 公開日: 2009-02-17, 最終更新日: 2024-11-13)

主引用文献

Artis, D.R.,Lin, J.J.,Zhang, C.,Wang, W.,Mehra, U.,Perreault, M.,Erbe, D.,Krupka, H.I.,England, B.P.,Arnold, J.,Plotnikov, A.N.,Marimuthu, A.,Nguyen, H.,Will, S.,Signaevsky, M.,Kral, J.,Cantwell, J.,Settachatgull, C.,Yan, D.S.,Fong, D.,Oh, A.,Shi, S.,Womack, P.,Powell, B.,Habets, G.,West, B.L.,Zhang, K.Y.,Milburn, M.V.,Vlasuk, G.P.,Hirth, K.P.,Nolop, K.,Bollag, G.,Ibrahim, P.N.,Tobin, J.F.
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
Proc.Natl.Acad.Sci.USA, 106:262-267, 2009

PubMed Abstract: In a search for more effective anti-diabetic treatment, we used a process coupling low-affinity biochemical screening with high-throughput co-crystallography in the design of a series of compounds that selectively modulate the activities of all three peroxisome proliferator-activated receptors (PPARs), PPARalpha, PPARgamma, and PPARdelta. Transcriptional transactivation assays were used to select compounds from this chemical series with a bias toward partial agonism toward PPARgamma, to circumvent the clinically observed side effects of full PPARgamma agonists. Co-crystallographic characterization of the lead molecule, indeglitazar, in complex with each of the 3 PPARs revealed the structural basis for its PPAR pan-activity and its partial agonistic response toward PPARgamma. Compared with full PPARgamma-agonists, indeglitazar is less potent in promoting adipocyte differentiation and only partially effective in stimulating adiponectin gene expression. Evaluation of the compound in vivo confirmed the reduced adiponectin response in animal models of obesity and diabetes while revealing strong beneficial effects on glucose, triglycerides, cholesterol, body weight, and other metabolic parameters. Indeglitazar has now progressed to Phase II clinical evaluations for Type 2 diabetes mellitus (T2DM).

PubMed: 19116277
DOI: 10.1073/pnas.0811325106

実験手法

X-RAY DIFFRACTION (2.4 Å)